GlaxoSmithKline PLC ADR
$ 51.52
0.49%
05 Jun - close price
- Market Cap 103,981,097,000 USD
- Current Price $ 51.52
- High / Low $ 51.97 / 51.27
- Stock P/E 13.57
- Book Value 11.95
- EPS 3.82
- Next Earning Report 2026-07-29
- Dividend Per Share $0.67
- Dividend Yield 3.51 %
- Next Dividend Date 2026-07-09
- ROA 0.10 %
- ROE 0.41 %
- 52 Week High 60.65
- 52 Week Low 34.17
About
GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.
Analyst Target Price
$57.94
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-29 | 2026-02-04 | 2025-10-29 | 2025-07-30 | 2025-04-30 | 2025-02-05 | 2024-10-30 | 2024-07-31 | 2024-05-01 | 2024-01-31 | 2023-11-01 | 2023-07-26 |
| Reported EPS | 1.26 | 0.7 | 1.46 | 1.24 | 1.2 | 0.58 | 1.29 | 1.11 | 1.08 | 0.73 | 1.22 | 1 |
| Estimated EPS | 1.16 | 0.62 | 1.26 | 1.11 | 1.04 | 0.49 | 1.16 | 0.98 | 0.94 | 0.77 | 1.14 | 0.87 |
| Surprise | 0.1 | 0.08 | 0.2 | 0.13 | 0.16 | 0.09 | 0.13 | 0.13 | 0.14 | -0.04 | 0.08 | 0.13 |
| Surprise Percentage | 8.6207% | 12.9032% | 15.873% | 11.7117% | 15.3846% | 18.3673% | 11.2069% | 13.2653% | 14.8936% | -5.1948% | 7.0175% | 14.9425% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-29 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 1.29 |
| Currency | GBP |
Previous Dividend Records
| Jul 2026 | Apr 2026 | Jan 2026 | Jan 1970 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-07-09 | 2026-04-09 | 2026-01-08 | None | 2025-07-10 | 2025-04-10 | 2025-01-09 | 2024-10-10 | 2024-07-11 | 2024-04-11 |
| Amount | $0.398072 | $0.485604 | $0.417088 | $0.428118 | $0.429088 | $0.400652 | $0.389052 | $0.385671 | $0.376185 | $0.4060608 |
Next Dividend Records
| Dividend per share (year): | $0.67 |
| Dividend Yield | 3.51% |
| Next Dividend Date | 2026-07-09 |
| Ex-Dividend Date | 2026-05-15 |
Recent News: GSK
2026-06-05 13:09:32
The article highlights recent clinical trial successes in the pharmaceutical industry, focusing on treatments for tough-to-treat diseases such as chronic hepatitis B, plaque psoriasis, and melanoma. GSK's bepirovirsen, Takeda's zasocitinib, and Moderna and Merck's personalized mRNA cancer vaccines are presented as significant advancements, offering new hope for functional cures, improved patient outcomes, and longer progression-free survival in these conditions. The article also notes the competitive landscape in these therapeutic areas and the potential market impact of these new drugs.
2026-06-04 16:08:00
This article analyzes GSK using algorithmic entry frameworks, highlighting weak near-term sentiment despite long-term strength. It provides specific trading strategies (Position, Momentum Breakout, Risk Hedging) with entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal strengths and support/resistance levels.
2026-06-04 10:39:15
Jefferies has reiterated its 'buy' rating and 2,500p price target for GSK PLC, identifying four near-term catalysts in its oncology pipeline following a recent healthcare conference. These catalysts include upcoming data presentations for its B7H3 antibody-drug conjugate, promising data for the IDRx-42 gastrointestinal stromal tumour treatment, renewed interest in the multiple myeloma treatment Blenrep, and the continued strategic use of external M&A alongside internal R&D, leveraging AI and digital pathology. The bank expects GSK's oncology division to significantly contribute to sales by 2031 and beyond.
2026-06-03 18:10:14
GSK is strategically focusing on precision oncology through internal innovation and external acquisitions. Key assets like B7-H4, B7-H3, dostarlimab, and velzatinib are advancing, with significant data readouts anticipated in the next year. These developments are expected to fuel long-term growth for the company.
2026-06-03 14:40:14
GSK's Specialty Medicines business is becoming its main growth driver, contributing over 40% of total sales with double-digit growth. This segment, covering Respiratory, Immunology & Inflammation, Oncology, and HIV, saw a 14% increase in sales in Q1 2026, fueled by strong demand for both existing products like Nucala and Dovato, and newer treatments such as Cabenuva, Apretude, Jemperli, and Ojjaara. The company anticipates low double-digit sales growth in this segment for 2026 and expects specialty medicines to comprise over 50% of total revenues by 2031 due to new product launches and a robust pipeline.
2026-06-03 12:09:38
UBS analyzes the UK equity market, noting that while earnings provide strong support, overall sentiment remains a drag. The bank suggests disciplined stock selection over broad index exposure, highlighting a fragile market score based on its REVS framework. Energy companies are significant drivers of earnings growth, but persistent structural crowding in certain sectors like consumer discretionary, healthcare, and industrials poses risks.
